Page de couverture de WolverHeme Happy Hour

WolverHeme Happy Hour

Auteur(s): Bernard Marini Anthony Perissinotti et al.
Écouter gratuitement

  • Résumé

  • Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
    Bernard Marini, Anthony Perissinotti, et al.
    Voir plus Voir moins
Épisodes
  • Episode 24: Myeloma Madness with the Myeloma Man

    Episode 24: Myeloma Madness with the Myeloma Man
    Apr 17 2024

    In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

    Voir plus Voir moins
    59 min
  • Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion

    Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
    Jan 25 2024

    In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!


    Abstracts discussed:

    • https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
    • https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
    • https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
    • https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
    • https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
    • https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
    • https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
    • https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)
    Voir plus Voir moins
    58 min
  • LymphOMG: Pouring Over Lymphoma Abstracts from ASH

    LymphOMG: Pouring Over Lymphoma Abstracts from ASH
    Dec 29 2023

    OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!


    Abstracts Discussed!

    1. SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html
    2. Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html
    3. BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html
    4. CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study)
    5. Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html
    6. POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20
    Voir plus Voir moins
    1 h et 13 min
Troubles et maladies Hygiene & Healthy Living
Voir plus Voir moins

Ce que les auditeurs disent de WolverHeme Happy Hour

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.